Trial Profile
RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled, Double-Blind, Randomized Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Apr 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Enoxaparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism
- Focus Registrational; Therapeutic Use
- Acronyms RECORD-3
- Sponsors Bayer; Bayer HealthCare
- 17 Jun 2019 This trial has been completed in Norway, according to European Clinical Trials Database.
- 12 Dec 2017 Results of exposure response analysis using patient data from RECORD-1, RECORD-2, RECORD-3 trials presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 18 Jan 2016 Retrospective analysis results published in the Annals of Pharmacotherapy